Patient-Focused Network Integration in BioPharma: Strategic Imperatives for the Years Ahead PDF
Preview Patient-Focused Network Integration in BioPharma: Strategic Imperatives for the Years Ahead
H Patient-Focused Business and Management a n d The biopharmaceutical industry as we know it today is going through a fi e massive upheaval as a result of the uncertainty of healthcare reform and ld Network increasing regulatory pricing pressure. A wake-up call to all sectors of the healthcare value chain, Patient-Focused Network Integration in P BioPharma: Strategic Imperatives for the Years Ahead explores patient- a Integration focused network integration as quite possibly the only way for organizational t i evolution to occur. The book discusses how to align enterprises with the e n patient at the center. It details the historical context of the biopharmaceutical t value chain and the current set of challenges facing the industry, and then - in BioPharma F details the author’s unique and sustainable agenda for change. o c u The book traces the critical but often ignored relationships among hospitals, s Strategic Imperatives for the Years Ahead insurance companies, biopharma manufacturers, government regulators, e d and clinical scientists. For too long, these parties have been operating in a void, without recognizing the interconnectedness of their objectives, N even though these objectives are often competing and misaligned. This e t book points out the gaps that exist and develops a set of recommendations w regarding disease treatments, clinical development of new products, and o collaboration among these players that can result in a sustainable solution r k to the healthcare mess. I n t Very simply, all parties in the healthcare value chain network must align e g their strategic planning to derive innovative solutions. It is only through r true collaboration and aligned thinking that the parties in the drug a t development, distribution, insurance payors, and hospital provider network i o can deal with the incredible complexity and massive challenges that face n the industry. The book provides a compelling maturity model that enables i n readers to gauge the level of network integration their enterprise is at today, B and where they need to move in the future. i o P h a r m K15373 a ISBN: 978-1-4665-5546-4 Rob Handfield, PhD 90000 www.crcpress.com 9 781466 555464 w w w. c r c p r e s s . c o m K15373 cvr mech.indd 1 5/13/13 10:52 AM Patient-Focused Network Integration in BioPharma Strategic Imperatives for the Years Ahead Patient-Focused Network Integration in BioPharma Strategic Imperatives for the Years Ahead Rob Handfield, PhD CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2013 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Version Date: 20130429 International Standard Book Number-13: 978-1-4665-5548-8 (eBook - PDF) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmit- ted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright. com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com Contents Preface ....................................................................................................ix Acknowledgments .................................................................................xi About the Author. ...............................................................................xiii Chapter 1 Patient-Focused Network Integration in the Life Sciences .................................................................1 Introduction: An Industry in Flux ............................................2 A Multiagent Simulation View .............................................3 A Blueprint for the Future .....................................................5 Growing Adoption of Price Restrictions by Regulators and Governments ...........................................5 Declining Research and Development (R&D) Productivity ...........................................................7 Emphasis on Pay for Performance and Personalized Medicine ..............................................8 Fragmentation of Mass Markets ....................................11 Emergence of Biotech and Biologics .............................11 Biosimilars versus Interchangeable Biologics ..............15 More Restrictive Regulations .........................................16 Increasing Use of Pervasive Monitoring .......................16 Changing Roles of Primary and Secondary Care .......17 Opportunities ........................................................................18 Overview of the Book ..............................................................20 Contents ................................................................................20 Summary ....................................................................................23 Customer Intimacy ...............................................................23 Partnerships with Other Players.........................................24 Cross-Functional Channel Design .....................................24 Chapter 2 An Evolutionary View of Healthcare Network Integration ........................................................................25 Core Elements for Network Integration ................................30 © 2010 Taylor & Francis Group, LLC v vi • Contents What Is a Maturity Model? .....................................................30 Governance: Healthcare ...........................................................36 Network Culture ........................................................................37 Performance Analytics ............................................................40 Patient and Disease Management ..........................................42 Administering and Deploying Technologies and Therapies ............................................................................43 The Case of Orphan Diseases ..................................................45 Comparative Cost-Effectiveness Models ...............................48 Talent and Competency Development ...................................50 The Impetus for Change ...........................................................51 Chapter 3 Healthcare Reform and the Provider Challenges Ahead .............................................................53 Outlook for Healthcare Providers ..........................................54 Challenges on the Horizon for Biopharmaceutical Companies in the Hospital Provider Environment ..............57 Personalized Medicine and Pay for Performance ............57 Reimbursement Models .......................................................57 Pay for Performance ........................................................58 Step Edit Therapy .............................................................58 Price Capping ...................................................................59 Outcome-Based Pricing ..................................................59 Accountable Care Organizations ..................................60 Regulatory Forecast for Healthcare Reform ..........................61 Evidence-Based Medicine (EBM): The Foundation for Pay for Performance ..........................62 Accountable Care Organizations (ACOs) .........................67 Healthcare Supply Chain Maturity ...................................68 Where Are Providers on the Maturity Curve? The Broken Venn Relationship ...........................................69 Physician View .................................................................71 Hospital Operations ........................................................72 Supply Chain Managers ..................................................73 Suppliers ............................................................................74 Lessons Learned and Future Directions ................................75 Integrated Distribution Network: Joint Replacement Case Study ..................................................................................77 © 2010 Taylor & Francis Group, LLC Contents • vii Chapter 4 Supply Chain Network Analytics for the Healthcare Industry Assessing Best of Breed ....................................83 Introduction ...............................................................................83 Methodology .............................................................................84 Assessing the Spend Management Landscape ................86 Defining Components of Supply Chain Spend Analytics ................................................................................89 Data Cleansing .................................................................91 Contract Management ....................................................98 Spend Analytics .............................................................101 Technology ......................................................................106 Service/Customer Responsiveness ...............................109 Aggregate Score across Categories ..............................111 Conclusion ................................................................................113 Appendix: Supplier Score Card Key .....................................116 Chapter 5 Electronic Collaboration in Life Sciences Supply Networks .........................................................................121 Introduction .............................................................................121 Methodology for the Study ...................................................123 Biopharmaceutical Ecosystem .........................................124 What Is the State of Electronic Collaboration in Biopharma? ....................................................................128 Dearth of Forecasting and Planning Capabilities .....132 Information Gaps in Current Electronic Collaboration .................................................................134 Performance Metrics That Drive Collaboration: What to Measure? How Often? ....................................138 Cost of Poor Visibility to Biopharma ..........................140 Characteristics of a Collaborative Supply Network .......143 Chapter 6 Maturing the Clinical Trial Supply Chain ...................145 Finding: Trial Complexity Is Increasing ..............................145 Finding: Multiple Perceptions Exist in Clinical Teams .........146 Concept of SCM Maturity ......................................................149 Clinical Trials Supply Chain Core Processes .................149 © 2010 Taylor & Francis Group, LLC viii • Contents Results ..................................................................................151 Overall Maturity ............................................................151 Plan: Clinical Supply Chain Planning .............................153 Forecast Accuracy ..........................................................153 Lack of Metrics ...............................................................156 Lack of Standard Processes ..........................................157 Source: Relationship Management with Key Clinical Suppliers ................................................................158 Make: Management of Clinical Contract Manufacturers (API, Fill and Finish, Label and Pack) .....160 Deliver: Clinical Logistics and Global Distribution ......164 Conclusions and Recommendations ....................................167 Chapter 7 Blueprint for the Future .................................................171 © 2010 Taylor & Francis Group, LLC
Description:The list of books you might like
